Phase I trial for ISTH0036 advanced glaucoma treatment

Article

Isarna Therapeutics has begun a Phase I clinical trial of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta (TGF-ß2), to treat advanced glaucoma.

Isarna Therapeutics has begun a Phase I clinical trial of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta (TGF-ß2), to treat advanced glaucoma.

The trial will evaluate the safety and long-term tolerability of ISTH0036 in 24 to 30 patients who have advanced glaucoma and are undergoing trabeculectomy due to uncontrollable elevated IOP. They will be treated with escalating doses of ISTH0036 and also will be monitored for IOP and visual field preservation.

“ISTH0036, with its expected three-directional activity, which includes blocking TGF-ß2-mediated trabecular meshwork alteration and inhibiting both direct optic nerve toxicity and scarring post trabeculectomy, has the potential to substantially alter the course of this disease and protect the patient’s vision,” Prof. Eugen Leo, Isarna’s head of clinical development, said in a statement. “Notably, ISTH0036 is currently the sole compound in clinical development worldwide that directly targets the core driver of the pathophysiology of glaucoma: TGF-ß2,” he added.

TGF-ß plays an important role in key pathways such as cell proliferation, cell differentiation, immune response and tissue modeling. Significantly elevated levels of TGF-ß have been identified in glaucomatous eyes in the anterior chamber, the vitreous, and optic nerve head. TGF-ß has been shown to directly cause increased IOP, a critical risk factor in the progression of glaucoma through complex interaction with the trabecular meshwork, leading to decreased aqueous humour outflow and has been linked to direct optic nerve toxicity.

Preclinical studies, according to Isarna, have demonstrated that ISTH0036 is highly potent and shows selective target engagement (TGF-ß2 mRNA and protein downregulation) consistent with long-lasting tissue uptake and pharmacodynamic effects.

The trial is being conducted at the University Hospitals of Mainz and Tuebingen, Germany. Isarna is headquartered in Germany and is registered as a Dutch BV as well as a U.S. corporation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.